Gigante, Bruna
ten Cate, Hugo http://orcid.org/0000-0001-7796-4463
Article History
First Online: 5 April 2023
Competing interests
: H.t.C. has received consultancy fees from Aleveron, AstraZeneca, Galapagos and Novostia and research funding from Bayer; all revenues are deposited at the CARIM Institute and labelled for research. H.t.C. is stockholder of Coagulation Profile, a spinoff diagnostic company of Maastricht University. B.G. declares no competing interests.